An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Selinexor (Primary) ; Dexamethasone; Ixazomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 17 Jan 2018 Planned number of patients changed from 24 to 38.
- 17 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 17 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.